These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 23113663)

  • 1. Short communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.
    Lopardo G; Bissio E; Espinola L; Gallego P; Stambullian M; Gadano A
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):456-60. PubMed ID: 23113663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of the UGT1A1*28 allele on unconjugated hyperbilirubinemia in HIV-positive patients receiving Atazanavir: a systematic review.
    Culley CL; Kiang TK; Gilchrist SE; Ensom MH
    Ann Pharmacother; 2013 Apr; 47(4):561-72. PubMed ID: 23548653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and pharmacogenetic factors affecting neonatal bilirubinemia following atazanavir treatment of mothers during pregnancy.
    Eley T; Huang SP; Conradie F; Zorrilla CD; Josipovic D; Botes M; Osiyemi O; Hardy H; Bertz R; McGrath D
    AIDS Res Hum Retroviruses; 2013 Oct; 29(10):1287-92. PubMed ID: 23782005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coadministration of atazanavir-ritonavir and zinc sulfate: impact on hyperbilirubinemia and pharmacokinetics.
    Moyle G; Else L; Jackson A; Back D; Yapa MH; Seymour N; Ringner-Nackter L; Karolia Z; Gazzard B; Boffito M
    Antimicrob Agents Chemother; 2013 Aug; 57(8):3640-4. PubMed ID: 23689708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomewide association study of atazanavir pharmacokinetics and hyperbilirubinemia in AIDS Clinical Trials Group protocol A5202.
    Johnson DH; Venuto C; Ritchie MD; Morse GD; Daar ES; McLaren PJ; Haas DW
    Pharmacogenet Genomics; 2014 Apr; 24(4):195-203. PubMed ID: 24557078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian atazanavir expanded access program and MASTER Cohorts.
    Torti C; Lapadula G; Antinori A; Quirino T; Maserati R; Castelnuovo F; Maggiolo F; De Luca A; Paraninfo G; Antonucci F; Migliorino G; Lazzarin A; Di Perri G; Rizzardini G; Esposito R; Carosi G
    Infection; 2009 Jun; 37(3):244-9. PubMed ID: 19471856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atazanavir-related hyperbilirubinaemia is not highlighted in the British National Formulary.
    Bradbeer C; Ngwenya S; Baker P; George M
    Int J STD AIDS; 2012 Oct; 23(10):759. PubMed ID: 23104755
    [No Abstract]   [Full Text] [Related]  

  • 8. Symptomatic hyperbilirubinemia secondary to dapsone-induced hemolysis and atazanavir therapy.
    East J; Blanton LS
    Antimicrob Agents Chemother; 2012 Feb; 56(2):1081-3. PubMed ID: 22123706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maternal atazanavir usage in HIV-infected pregnant women and the risk of maternal and neonatal hyperbilirubinemia.
    Atrio JM; Sperling RS; Posada R; Rodriguez Caprio G; Chen KT
    J Acquir Immune Defic Syndr; 2013 Aug; 63(5):e158-9. PubMed ID: 23970241
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenetic testing can identify patients taking atazanavir at risk for hyperbilirubinemia.
    Avihingsanon A; Tongkobpetch S; Kerr SJ; Punyawudho B; Suphapeetiporn K; Gorowara M; Ruxrungtham K; Shotelersuk V
    J Acquir Immune Defic Syndr; 2015 May; 69(1):e36-7. PubMed ID: 25622064
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers.
    Ferraris L; Viganò O; Peri A; Tarkowski M; Milani G; Bonora S; Adorni F; Gervasoni C; Clementi E; Di Perri G; Galli M; Riva A
    J Antimicrob Chemother; 2012 Sep; 67(9):2236-42. PubMed ID: 22661571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen.
    Boffito M; Kurowski M; Kruse G; Hill A; Benzie AA; Nelson MR; Moyle GJ; Gazzard BG; Pozniak AL
    AIDS; 2004 Jun; 18(9):1291-7. PubMed ID: 15362661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study.
    McDonald C; Uy J; Hu W; Wirtz V; Juethner S; Butcher D; McGrath D; Farajallah A; Moyle G
    AIDS Patient Care STDS; 2012 May; 26(5):259-64. PubMed ID: 22404426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.
    Horberg M; Klein D; Hurley L; Silverberg M; Towner W; Antoniskis D; Kovach D; Mogyoros M; Blake W; Dobrinich R; Dodge W
    HIV Clin Trials; 2008; 9(6):367-74. PubMed ID: 19203902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atazanavir and other determinants of hyperbilirubinemia in a cohort of 1150 HIV-positive patients: results from 9 years of follow-up.
    Laprise C; Baril JG; Dufresne S; Trottier H
    AIDS Patient Care STDS; 2013 Jul; 27(7):378-86. PubMed ID: 23829329
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C-->T polymorphism at the multidrug resistance gene 1.
    Rodríguez Nóvoa S; Barreiro P; Rendón A; Barrios A; Corral A; Jiménez-Nacher I; González-Lahoz J; Soriano V
    Clin Infect Dis; 2006 Jan; 42(2):291-5. PubMed ID: 16355344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.
    Bissio E; Lopardo GD
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):415-7. PubMed ID: 23121190
    [No Abstract]   [Full Text] [Related]  

  • 18. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of atazanavir in patients with end-stage liver disease.
    Guaraldi G; Cocchi S; Motta A; Ciaffi S; Codeluppi M; Bonora S; Di Benedetto F; Masetti M; Floridia M; Baroncelli S; Pinetti D; Bertolini A; Gerunda GE; Esposito R
    Infection; 2009 Jun; 37(3):250-5. PubMed ID: 19471855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of atazanavir-associated hyperbilirubinemia in Korean HIV patients: 30 months follow-up results in a population with low UDP-glucuronosyltransferase1A1*28 allele frequency.
    Choe PG; Park WB; Song JS; Kim NH; Song KH; Park SW; Kim HB; Kim NJ; Oh MD
    J Korean Med Sci; 2010 Oct; 25(10):1427-30. PubMed ID: 20890421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.